Donald E. Kohan

13.7k total citations · 3 hit papers
227 papers, 10.7k citations indexed

About

Donald E. Kohan is a scholar working on Molecular Biology, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Donald E. Kohan has authored 227 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Molecular Biology, 93 papers in Physiology and 73 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Donald E. Kohan's work include Nitric Oxide and Endothelin Effects (85 papers), Ion Transport and Channel Regulation (80 papers) and Renin-Angiotensin System Studies (48 papers). Donald E. Kohan is often cited by papers focused on Nitric Oxide and Endothelin Effects (85 papers), Ion Transport and Channel Regulation (80 papers) and Renin-Angiotensin System Studies (48 papers). Donald E. Kohan collaborates with scholars based in United States, Netherlands and United Kingdom. Donald E. Kohan's co-authors include Peter K. Stricklett, David M. Pollock, Alisa K. Hughes, Raoul D. Nelson, Paola Fioretto, Matthias Barton, Yuqiang Ge, James F. List, Weihua Tang and Edward W. Inscho and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Donald E. Kohan

226 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endothelin

2016 564 citations Anthony P. Davenport, Kelly A. Hyndman et al. Pharmacological Reviews profile →
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

2013 529 citations Donald E. Kohan et al. Kidney International profile →
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

2005 507 citations Donald E. Kohan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald E. Kohan United States	52	4.2k	3.5k	3.3k	2.6k	1.9k	227	10.7k
Kimio Tomita Japan	46	3.5k 0.8×	1.7k 0.5×	2.7k 0.8×	1.6k 0.6×	3.2k 1.6×	192	11.3k
Berthold Hocher Germany	53	2.2k 0.5×	1.8k 0.5×	2.0k 0.6×	1.6k 0.6×	1.7k 0.9×	355	9.4k
Matthew D. Breyer United States	70	6.6k 1.6×	2.6k 0.8×	1.9k 0.6×	2.8k 1.1×	2.8k 1.4×	204	16.0k
Takao Saruta Japan	64	3.8k 0.9×	3.0k 0.9×	5.9k 1.8×	4.8k 1.9×	1.5k 0.8×	531	15.5k
Iekuni Ichikawa United States	69	4.6k 1.1×	1.5k 0.4×	5.2k 1.6×	3.1k 1.2×	4.7k 2.4×	216	13.9k
Norikazu Maeda Japan	54	3.6k 0.9×	5.4k 1.5×	3.3k 1.0×	2.2k 0.8×	551 0.3×	126	13.6k
Atsunori Kashiwagi Japan	55	4.2k 1.0×	2.1k 0.6×	1.4k 0.4×	3.5k 1.3×	1.2k 0.6×	231	11.3k
Hitoshi Nishizawa Japan	50	3.2k 0.8×	5.1k 1.4×	3.2k 1.0×	2.6k 1.0×	551 0.3×	162	13.2k
Julie R. Ingelfinger United States	57	3.4k 0.8×	902 0.3×	3.2k 1.0×	2.2k 0.9×	2.0k 1.1×	253	10.6k
Kazuaki Shimamoto Japan	61	3.6k 0.9×	2.1k 0.6×	5.7k 1.7×	2.8k 1.1×	581 0.3×	449	14.4k

Countries citing papers authored by Donald E. Kohan

Since Specialization

Citations

This map shows the geographic impact of Donald E. Kohan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald E. Kohan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald E. Kohan more than expected).

Fields of papers citing papers by Donald E. Kohan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald E. Kohan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald E. Kohan. The network helps show where Donald E. Kohan may publish in the future.

Co-authorship network of co-authors of Donald E. Kohan

This figure shows the co-authorship network connecting the top 25 collaborators of Donald E. Kohan. A scholar is included among the top collaborators of Donald E. Kohan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald E. Kohan. Donald E. Kohan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kohan, Donald E., et al.. (2024). Endothelin receptor antagonists in chronic kidney disease. Nature Reviews Nephrology. 21(3). 175–188. 13 indexed citations

2.

Hendry, Bruce M., et al.. (2023). Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety. Journal of the American Society of Nephrology. 34(11S). 799–799. 1 indexed citations

3.

Veenit, Vandana, Hiddo J.L. Heerspink, Christine Ahlström, et al.. (2023). The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrology Dialysis Transplantation. 38(10). 2289–2297. 12 indexed citations

4.

Ramkumar, Nirupama, Deborah Stuart, Chunyan Hu, et al.. (2021). Loss of Soluble (Pro)renin Receptor Attenuates Angiotensin-II Induced Hypertension and Renal Injury. Circulation Research. 129(1). 50–62. 26 indexed citations

5.

Kohan, Donald E., et al.. (2021). Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Current Opinion in Nephrology & Hypertension. 30(4). 456–465. 28 indexed citations

6.

Gao, Yang, Chunyan Hu, Deborah Stuart, et al.. (2020). Nephron-Specific Disruption of Polycystin-1 Induces Cyclooxygenase-2–Mediated Blood Pressure Reduction Independent of Cystogenesis. Journal of the American Society of Nephrology. 31(6). 1243–1254. 5 indexed citations

7.

Benigni, Ariela, Simona Buelli, & Donald E. Kohan. (2020). Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatric Nephrology. 36(4). 763–775. 16 indexed citations

8.

Kohan, Donald E.. (2017). An Unexpected Lesson in Global Nephrology. The Nephron journals/Nephron journals. 138(3). 229–230. 1 indexed citations

9.

Poulsen, Søren Brandt, et al.. (2017). Role of adenylyl cyclase 6 in the development of lithium-induced nephrogenic diabetes insipidus. JCI Insight. 2(7). e91042–e91042. 19 indexed citations

10.

Ramkumar, Nirupama, Deborah Stuart, Elena Mironova, et al.. (2016). Renal tubular epithelial cell prorenin receptor regulates blood pressure and sodium transport. American Journal of Physiology-Renal Physiology. 311(1). F186–F194. 51 indexed citations

11.

Davenport, Anthony P., Kelly A. Hyndman, Neeraj Dhaun, et al.. (2016). Endothelin. Pharmacological Reviews. 68(2). 357–418. 564 indexed citations breakdown →

12.

Strait, Kevin A., et al.. (2012). Na delivery and ENaC mediate flow regulation of collecting duct endothelin-1 production. American Journal of Physiology-Renal Physiology. 302(10). F1325–F1330. 22 indexed citations

13.

Barton, Matthias & Donald E. Kohan. (2011). Endothelin Antagonists in Clinical Trials: Lessons Learned. Contributions to nephrology. 172. 255–260. 20 indexed citations

14.

Rabelink, Ton J. & Donald E. Kohan. (2011). Endothelin Receptor Blockade in Patients with Diabetic Nephropathy. Contributions to nephrology. 172. 235–242. 6 indexed citations

15.

Kohan, Donald E.. (2009). Biology of endothelin receptors in the collecting duct. Kidney International. 76(5). 481–486. 24 indexed citations

16.

Schneider, Markus P., Yuqiang Ge, David M. Pollock, Jennifer S. Pollock, & Donald E. Kohan. (2008). Collecting Duct-Derived Endothelin Regulates Arterial Pressure and Na Excretion via Nitric Oxide. Hypertension. 51(6). 1605–1610. 74 indexed citations

17.

Ge, Yuqiang, Peter K. Stricklett, Alisa K. Hughes, Masashi Yanagisawa, & Donald E. Kohan. (2005). Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. American Journal of Physiology-Renal Physiology. 289(4). F692–F698. 77 indexed citations

18.

Ahn, Dowhan, Yuqiang Ge, Peter K. Stricklett, et al.. (2004). Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retention. Journal of Clinical Investigation. 114(4). 504–511. 178 indexed citations

19.

Ahn, Dowhan, Yuqiang Ge, Peter K. Stricklett, et al.. (2004). Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retention. Journal of Clinical Investigation. 114(4). 504–511. 206 indexed citations

20.

Kohan, Donald E.. (1993). Autocrine Role of Endothelin in Rat Inner Medullary Collecting Duct: Inhibition of AVP-Induced cAMP Accumulation. Journal of Cardiovascular Pharmacology. 22(Supplement 8). S174–S176. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact